277 related articles for article (PubMed ID: 22160844)
1. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data.
Bassyouni IH; Gheita TA; Talaat RM
Rheumatology (Oxford); 2011 Nov; 50(11):2108-12. PubMed ID: 21890620
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage.
Ogawa F; Shimizu K; Hara T; Muroi E; Hasegawa M; Takehara K; Sato S
Clin Exp Rheumatol; 2008; 26(4):659-62. PubMed ID: 18799101
[TBL] [Abstract][Full Text] [Related]
8. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
Yanaba K; Yoshizaki A; Asano Y; Kadono T; Sato S
Clin Rheumatol; 2011 Jun; 30(6):825-30. PubMed ID: 21246230
[TBL] [Abstract][Full Text] [Related]
9. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2012 Aug; 22(4):576-83. PubMed ID: 22075605
[TBL] [Abstract][Full Text] [Related]
11. Growth Differentiation Factor-15 (GDF-15) Level and Relation to Clinical Manifestations in Egyptian Systemic Sclerosis patients: Preliminary Data.
Gamal SM; Elgengehy FT; Kamal A; El Bakry SA; Shabaan E; Elgendy A; Bassyouni IH
Immunol Invest; 2017 Oct; 46(7):703-713. PubMed ID: 28872977
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
Yanaba K; Komura K; Kodera M; Matsushita T; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
[TBL] [Abstract][Full Text] [Related]
14. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function.
Kawashiri SY; Nishino A; Igawa T; Takatani A; Shimizu T; Umeda M; Fukui S; Okada A; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakashima M; Mizokami A; Matsuoka N; Migita K; Ogawa F; Ikeda S; Maemura K; Nakamura H; Origuchi T; Maeda T; Kawakami A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):102-108. PubMed ID: 29652651
[TBL] [Abstract][Full Text] [Related]
15. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis.
Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Arch Dermatol Res; 2013 Jan; 305(1):17-23. PubMed ID: 23053221
[TBL] [Abstract][Full Text] [Related]
16. Increased serum pentraxin 3 in patients with systemic sclerosis.
Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis.
Yanaba K; Yoshizaki A; Asano Y; Kadono T; Sato S
J Rheumatol; 2011 Oct; 38(10):2193-7. PubMed ID: 21807780
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
Ogawa F; Shimizu K; Muroi E; Hara T; Hasegawa M; Takehara K; Sato S
Rheumatology (Oxford); 2006 Jul; 45(7):815-8. PubMed ID: 16449367
[TBL] [Abstract][Full Text] [Related]
19. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
20. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
